Work with thought leaders and academic experts in pharmacology

Companies can greatly benefit from working with experts in the field of Pharmacology. These researchers possess in-depth knowledge of drug interactions, mechanisms of action, and therapeutic applications. By collaborating with them, companies can enhance their research and development efforts, gain insights into new drug targets, optimize drug formulations, and improve clinical trial design. Pharmacology experts can also provide valuable guidance in regulatory affairs, ensuring compliance with safety and efficacy standards. Additionally, their expertise can help companies identify potential drug-drug interactions and adverse effects, leading to safer and more effective medications. Overall, partnering with Pharmacology thought leaders can accelerate innovation, improve product quality, and drive business growth.

Experts on NotedSource with backgrounds in pharmacology include Dushani L. Palliyaguru, Ph.D., Aimee Eggler, Regan Hamel, Jeffrey Townsend, Katie Barr, Laura Schulze, Luke Connelly, Abbas Alameer, Azeezat Azeez, Nora S Vyas, Ph.D., Marie Mooney, PhD, Giuliana Noratto, Lee Weinstein, ARNOLD RAYMOND, Norman Farb, Marina Baretti, Samiul Amin, Abiodun Adewuya, Professor Sinead McGilloway, Sumeet K. Tiwari, Katelyn Katelyn Masiuk, and Radha Kushwaha.

Katie Barr

Warrington
Bioinformatician and developer with strong academic and commercial experience
Most Relevant Research Interests
Pharmacology
Other Research Interests (19)
Genomics, Metagenomics, Transcriptomics, Data analysis, Software development, Algorithms
Computer Science Applications
Atomic and Molecular Physics, and Optics
General Engineering
General Materials Science
And 14 more
About
Katie Barr is a bioinformatician with a strong background in computer science. She received her Ph.D in Quantum Information from the University of Leeds in 2013. She also holds an MSc in Mathematical logic and the theory of computation from the University of Manchester, and a BSc in Physics and Philosophy with study in Continental Europe from the University of Bristol. Katie has extensive experience working in the fields of bioinformatics and software development. She has worked as a scientific programmer at the Earlham Institute, a postdoctoral bioinformatician in the Nanomedicine group at the University of Manchester, and is now an Associate Principal Scientist in Bioinformatics at Kromek. Katie is passionate about using her knowledge and skills to improve the lives of others and she is dedicated to the advancement of science and technology. She believes in the power of collaboration and works to create meaningful partnerships between industry and academia.
Most Relevant Publications (1+)

9 total publications

Deep Tissue Translocation of Graphene Oxide Sheets in Human Glioblastoma 3D Spheroids and an Orthotopic Xenograft Model

Advanced Therapeutics / Oct 09, 2020

de Lázaro, I., Sharp, P., Gurcan, C., Ceylan, A., Stylianou, M., Kisby, T., Chen, Y., Vranic, S., Barr, K., Taheri, H., Ozen, A., Bussy, C., Yilmazer, A., & Kostarelos, K. (2020). Deep Tissue Translocation of Graphene Oxide Sheets in Human Glioblastoma 3D Spheroids and an Orthotopic Xenograft Model. Advanced Therapeutics, 4(1). Portico. https://doi.org/10.1002/adtp.202000109

Laura Schulze

TORONTO, Ontario, Canada
Passionate mental health researcher with a PhD in Neuroscience, dedicated to fostering innovation and empathy in accessible and holistic mental health care.
Most Relevant Research Interests
Pharmacology
Other Research Interests (4)
Neuroscience
Mental Health
Psychiatry and Mental health
Biological Psychiatry
About
Hi! My name is Laura, and I am a mental health researcher and neuroscientist from Toronto. I have a diverse background in clinical research, industry/startup involvement, and advisory roles. My passion lies in exploring the potential of neurotech and utilizing data-driven insights to understand and support mental well-being. I also deeply value the role of community and collective well-being in fostering positive mental health outcomes.
Most Relevant Publications (4+)

8 total publications

Effect of antipsychotic pharmacotherapy on clinical outcomes of intermittent theta-burst stimulation for refractory depression

Journal of Psychopharmacology / Nov 11, 2016

Schulze, L., Remington, G., Giacobbe, P., Kennedy, S. H., Blumberger, D. M., Daskalakis, Z. J., & Downar, J. (2016). Effect of antipsychotic pharmacotherapy on clinical outcomes of intermittent theta-burst stimulation for refractory depression. Journal of Psychopharmacology, 31(3), 312–319. https://doi.org/10.1177/0269881116675516

Cognitive safety of dorsomedial prefrontal repetitive transcranial magnetic stimulation in major depression

European Neuropsychopharmacology / Jul 01, 2016

Schulze, L., Wheeler, S., McAndrews, M. P., Solomon, C. J. E., Giacobbe, P., & Downar, J. (2016). Cognitive safety of dorsomedial prefrontal repetitive transcranial magnetic stimulation in major depression. European Neuropsychopharmacology, 26(7), 1213–1226. https://doi.org/10.1016/j.euroneuro.2016.04.004

Antipsychotic response in first-episode schizophrenia: efficacy of high doses and switching

European Neuropsychopharmacology / Sep 01, 2013

Agid, O., Schulze, L., Arenovich, T., Sajeev, G., McDonald, K., Foussias, G., Fervaha, G., & Remington, G. (2013). Antipsychotic response in first-episode schizophrenia: efficacy of high doses and switching. European Neuropsychopharmacology, 23(9), 1017–1022. https://doi.org/10.1016/j.euroneuro.2013.04.010

Clinical, behavioral, and neural measures of reward processing correlate with escitalopram response in depression: a Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report

Neuropsychopharmacology / Apr 29, 2020

Dunlop, K., Rizvi, S. J., Kennedy, S. H., Hassel, S., Strother, S. C., Harris, J. K., Zamyadi, M., Arnott, S. R., Davis, A. D., Mansouri, F., Schulze, L., Ceniti, A. K., Lam, R. W., Milev, R., Rotzinger, S., Foster, J. A., Frey, B. N., Parikh, S. V., Soares, C. N., … Downar, J. (2020). Clinical, behavioral, and neural measures of reward processing correlate with escitalopram response in depression: a Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report. Neuropsychopharmacology, 45(8), 1390–1397. https://doi.org/10.1038/s41386-020-0688-x

Luke Connelly

Professor of Health Economics, The University of Queensland, CBEH
Most Relevant Research Interests
Pharmacology
Other Research Interests (51)
Health economics
insurance
Public Health, Environmental and Occupational Health
Safety, Risk, Reliability and Quality
Human Factors and Ergonomics
And 46 more
About
Luke Connelly is Professor of Health Economics at the Centre for the Business and Economics of Health. He also holds a Professorial appointment (part-time) at The University of Bologna, to which he was appointed in 2017 via the Italian “Direct Call” ([link](https://www.unibo.it/sitoweb/luke.connelly/en)) process. In 2019 he was appointed as Honorary Professor at The University of Sydney. His main interests are in health economics and insurance economics and the effects of institutions (including legal constructs) on incentives and behaviour. He has also worked in other fields of applied microeconomics, including education economics and transport economics. His publications include papers in *Review of Income and Wealth*, *Health Economics*, *Journal of Health Economics*, *Journal of Risk and Insurance*, *Geneva Papers on Risk and Insurance*, *Accident Analysis and Prevention*, *Journal of Law and Medicine*, *Journal of Clinical Epidemiology*, *European Journal of Health Economics*, *International Journal of Health Economics and Finance*, *Social Science and Medicine*, *Economic Papers*, *Economic Analysis and Policy*, *Journal of Transport Economics and Policy*, *Labour Economics*, *Economics and Human Biology* as well as in a range of clinical journals, including *Lancet*. Luke has served on a number of public committees including the Medical Services Advisory Committee (MSAC), which advises the Australian Minister for Health on the safety, efficacy, effectiveness, and cost-effectiveness of new and extant listings on Australia's Medicare Benefits Schedule. He has extensive service on other public committees and taskforces as well as extensive teaching and consulting engagements with industry. Over his career he has been a chief investigator on research grants and contracts totalling more than $67m. He is a member of the Editorial Boards of European Journal of Health Economics and the International Journal on Environmental Research and Public Health. He is a member of the International Health Economics Association's Arrow Awards Committee, which awards an annual prize in honour of Nobel Laureate Kenneth Arrow for the best paper in the field. He is currently Guest Editor (with Christophe Courbage) on a Special Issue of the Geneva Papers on Risk and Insurance on Insurance and Emerging Health Risks. His current research interests include health service innovations to improve the health of people with chronic kidney disease(CKD). Ongoing interests include the economics of disability and insurance, compensable injury compensation schemes, and the determinants of health. Luke enjoys and has considerable experience teaching economics and health economics at both the graduate and undergraduate levels. In 2014 he was awarded the School of Economics Distinguished Teaching Award for his teaching on UQ's Master of Health Economics Program. In July 2016 and July 2019 he also taught summer schools in Health Economics and the Economics of Insurance at The University of Lucerne, Switzerland. Over the past 10 years he has been a chief investigator on grants totalling more than $70m.
Most Relevant Publications (2+)

105 total publications

Sustainability of Publicly Funded Health Care Systems: What Does Behavioural Economics Offer?

PharmacoEconomics / Sep 08, 2020

Connelly, L. B., & Birch, S. (2020). Sustainability of Publicly Funded Health Care Systems: What Does Behavioural Economics Offer? PharmacoEconomics, 38(12), 1289–1295. https://doi.org/10.1007/s40273-020-00955-x

Balancing the number and size of sites: an economic approach to the optimal design of cluster samples

Controlled Clinical Trials / Oct 01, 2003

Connelly, L. B. (2003). Balancing the number and size of sites: an economic approach to the optimal design of cluster samples. Controlled Clinical Trials, 24(5), 544–559. https://doi.org/10.1016/s0197-2456(03)00093-x

Abbas Alameer

Assistant Professor of Bioinformatics at Kuwait University
Most Relevant Research Interests
Pharmacology
Other Research Interests (10)
Bioinformatics
Computational Mathematics
Computational Theory and Mathematics
Computer Science Applications
Molecular Biology
And 5 more
About
Abbas Alameer is an Assistant Professor of Bioinformatics at Kuwait University. He received his PhD in Bioinformatics and Molecular Modelling from the University of Leicester in 2014 and his MRes in Bioinformatics and Computational Biology from the University of Leeds in 2006. He has over 10 years of experience in bioinformatics related research and teaching. His research focuses on the computational analysis and modelling of biological molecules, and the development of novel algorithms and Bioinformatics tools. He has published several articles in leading journals in the field and has presented his work at international conferences.
Most Relevant Publications (1+)

3 total publications

Whole-Genome and Targeted-Amplicon Sequencing of Fluconazole-Susceptible and -Resistant Candida parapsilosis Isolates from Kuwait Reveals a Previously Undescribed N1132D Polymorphism in CDR1

Antimicrobial Agents and Chemotherapy / Jan 20, 2021

Asadzadeh, M., Dashti, M., Ahmad, S., Alfouzan, W., & Alameer, A. (2021). Whole-Genome and Targeted-Amplicon Sequencing of Fluconazole-Susceptible and -Resistant Candida parapsilosis Isolates from Kuwait Reveals a Previously Undescribed N1132D Polymorphism in CDR1. Antimicrobial Agents and Chemotherapy, 65(2). https://doi.org/10.1128/aac.01633-20

Nora S Vyas, Ph.D.

Associate Professor of Mental Health, with interest in civic engagement and partnerships
Most Relevant Research Interests
Pharmacology
Other Research Interests (26)
Psychosis
neuroimaging
neuropsychology
mindfulness
neurodevelopmental disorders
And 21 more
About
Dr Nora S Vyas is an Associate Professor in Psychology at the Department of Psychology, Kingston University. She joined Kingston University in 2012, and previously held a Senior Lecturer position at Middlesex University. Dr Vyas completed her PhD in psychiatry at the Institute of Psychiatry, Psychology and Neuroscience (IoPPN), University of London in 2008. Following her PhD, she worked at the Child Psychiatry Branch, National Institutes of Health (Washington DC, USA) as a Lindemann Trust Fellow (English-Speaking Union), preceded by a Fulbright Distinguished Fellowship in 2010. Dr Vyas teaches at undergraduate and postgraduate level in child/adolescent and adult mental health, health psychology, and clinical/cognitive neuroscience. Her research focuses on using clinical, cognitive, and imaging techniques to study individuals with serious mental health problems such as bipolar disorder and schizophrenia. She applies these skills in other fields such as oncology and mindfulness. Her research specialism is early-onset psychosis, and she has published her work widely.
Most Relevant Publications (2+)

30 total publications

Recent Developments in Neurochemical Imaging in Schizophrenia: An Update

Current Medicinal Chemistry / Jan 01, 2013

S. Vyas, N., H. Patel, N., Herscovitch, P., K. Puri, B., & Lanzenberger, R. (2013). Recent Developments in Neurochemical Imaging in Schizophrenia: An Update. Current Medicinal Chemistry, 20(3), 351–356. https://doi.org/10.2174/092986713804870765

Can genetics inform the management of cognitive deficits in schizophrenia?

Journal of Psychopharmacology / Feb 10, 2012

Vyas, N. S., Shamsi, S. A., Malhotra, A. K., Aitchison, K. J., & Kumari, V. (2012). Can genetics inform the management of cognitive deficits in schizophrenia? Journal of Psychopharmacology, 26(3), 334–348. https://doi.org/10.1177/0269881111434623

Giuliana Noratto

Food Scientist PhD and Registered Dietician - Texas A&M University
Most Relevant Research Interests
Pharmacology
Other Research Interests (40)
Food Science
human nutrition
disease prevention and treatment
Nutrition
Human Health
And 35 more
About
Dr. Giuliana Noratto is a senior associate research scientist at Texas A&M AgriLife. She received her Ph.D. in food science and technology from Texas A&M University System, and her M.Sc. in food science and technology from Universidad Nacional Agraria La Molina. She also holds a B.S. in food science and technology from Universidad Nacional Agraria La Molina. Dr. Noratto’s research interests include food safety and quality, sensory science, and food processing.
Most Relevant Publications (4+)

91 total publications

Phytocomplexes from liquorice (Glycyrrhiza glabra L.) leaves — Chemical characterization and evaluation of their antioxidant, anti-genotoxic and anti-inflammatory activity

Fitoterapia / Jun 01, 2011

Siracusa, L., Saija, A., Cristani, M., Cimino, F., D’Arrigo, M., Trombetta, D., Rao, F., & Ruberto, G. (2011). Phytocomplexes from liquorice (Glycyrrhiza glabra L.) leaves — Chemical characterization and evaluation of their antioxidant, anti-genotoxic and anti-inflammatory activity. Fitoterapia, 82(4), 546–556. https://doi.org/10.1016/j.fitote.2011.01.009

Calotropis Procera Induced Caspase-Dependent Apoptosis and Impaired Akt/mTOR Signaling in 4T1 Breast Cancer Cells

Anti-Cancer Agents in Medicinal Chemistry / Nov 01, 2022

Rabelo, A. C. S., Miglino, M. A., Arbizu, S., Carreira, A. C. O., Filho, A. J. C., Carneiro, F. J. C., Layosa, M. A. A., & Noratto, G. (2022). Calotropis Procera Induced Caspase-Dependent Apoptosis and Impaired Akt/mTOR Signaling in 4T1 Breast Cancer Cells. Anti-Cancer Agents in Medicinal Chemistry, 22(18), 3136–3147. https://doi.org/10.2174/1871520622666220608122154

The role of dietary polyphenols in osteosarcoma: A possible clue about the molecular mechanisms involved in a process that is just in its infancy

Journal of Food Biochemistry / Dec 07, 2021

Rabelo, A. C. S., Borghesi, J., & Noratto, G. D. (2021). The role of dietary polyphenols in osteosarcoma: A possible clue about the molecular mechanisms involved in a process that is just in its infancy. Journal of Food Biochemistry, 46(1). Portico. https://doi.org/10.1111/jfbc.14026

Flavonol-rich fractions of yaupon holly leaves (Ilex vomitoria, Aquifoliaceae) induce microRNA-146a and have anti-inflammatory and chemopreventive effects in intestinal myofribroblast CCD-18Co cells

Fitoterapia / Jun 01, 2011

Noratto, G. D., Kim, Y., Talcott, S. T., & Mertens-Talcott, S. U. (2011). Flavonol-rich fractions of yaupon holly leaves (Ilex vomitoria, Aquifoliaceae) induce microRNA-146a and have anti-inflammatory and chemopreventive effects in intestinal myofribroblast CCD-18Co cells. Fitoterapia, 82(4), 557–569. https://doi.org/10.1016/j.fitote.2011.01.013

Norman Farb

Associate Professor at University of Toronto - Mississauga
Most Relevant Research Interests
Pharmacology
Other Research Interests (39)
Mindfulness- Emotion - Affect - Attention - Neuroscience - Interoception
Cognitive Neuroscience
Experimental and Cognitive Psychology
General Medicine
General Psychology
And 34 more
About
Norman Farb, PhD, is an Associate Professor of Psychology at the University of Toronto Mississauga, where he directs the Regulatory and Affective Dynamics laboratory (www.radlab.zone). He studies the psychology of well-being, focusing on mental habits, such as how we think about ourselves and interpret our emotions. He is particularly interested in why people differ in their resilience to stress, depression, and anxiety. Prof. Farb's work currently explores online training to support wellbeing, as well as neuroimaging to understand how emotional reactions predict mental health over the lifespan.
Most Relevant Publications (3+)

96 total publications

Microdosing psychedelics: personality, mental health, and creativity differences in microdosers

Psychopharmacology / Jan 02, 2019

Anderson, T., Petranker, R., Rosenbaum, D., Weissman, C. R., Dinh-Williams, L.-A., Hui, K., Hapke, E., & Farb, N. A. S. (2019). Microdosing psychedelics: personality, mental health, and creativity differences in microdosers. Psychopharmacology, 236(2), 731–740. https://doi.org/10.1007/s00213-018-5106-2

First-episode major depression and treatment with escitalopram: an fMRI study

European Neuropsychopharmacology / Oct 01, 2016

Ravindran, A., Harkness, K., Ravindran, L., Jain, T., & Farb, N. (2016). First-episode major depression and treatment with escitalopram: an fMRI study. European Neuropsychopharmacology, 26, S467. https://doi.org/10.1016/s0924-977x(16)31464-x

Cognitive behavioural therapy enhances compensatory neural circuitry in obsessive compulsive disorder

European Neuropsychopharmacology / Oct 01, 2016

Ravindran, A., Richter, M., Jain, T., Ravindran, L., Rector, N., & Farb, N. (2016). Cognitive behavioural therapy enhances compensatory neural circuitry in obsessive compulsive disorder. European Neuropsychopharmacology, 26, S621–S622. https://doi.org/10.1016/s0924-977x(16)31709-6

Marina Baretti

Baltimore, Maryland, United States of America
I am a clinical translational researcher in gastrointestinal (GI) oncology, collaborating closely with laboratory-based researchers to move laboratory findings into patients and to answer important clinical questions.
Most Relevant Research Interests
Pharmacology
Other Research Interests (15)
Oncology
Pharmacology (medical)
Hematology
Gastroenterology
Hepatology
And 10 more
About
Throughout my training, I have been focused toward my ultimate goal of becoming a clinical translational researcher in gastrointestinal (GI) oncology, collaborating closely with laboratory-based researchers to move laboratory findings into patients and to answer important clinical questions. My clinical research is centered on the development of novel agents in GI cancers, with particular interest in combinatorial approaches of epigenetic therapies and immunotherapies combinations. I ran the first phase II study of combination epigenetic therapy and immunotherapy in advanced pancreatic adenocarcinoma and cholangiocarcinoma, working with a collaborative team that incorporates leading experts in cancer immunology, epigenetics and drug development. I was awarded the 2018 ASCO Conquer Cancer Foundation Young Investigator Award for this project.  Together with Dr. Yarchoan, we are running a clinical trial of a novel neoantigen-specific vaccine in combination with immune checkpoint inhibitors for advanced fibrolamellar carcinoma (FLC) (NCT04248569). My laboratory focus has been on developing and validating a preclinical mouse model of FLC to investigate mechanisms underlying FLC pathogenesis, and will become a critical tool for investigating novel therapeutic strategies in FLC.
Most Relevant Publications (2+)

57 total publications

DNA mismatch repair in cancer

Pharmacology & Therapeutics / Sep 01, 2018

Baretti, M., & Le, D. T. (2018). DNA mismatch repair in cancer. Pharmacology & Therapeutics, 189, 45–62. https://doi.org/10.1016/j.pharmthera.2018.04.004

Emergence of KRAS-mutation in liver metastases after an anti-EGFR treatment in patient with colorectal cancer: Are we aware of the therapeutic impact of intratumor heterogeneity?

Cancer Biology & Therapy / Apr 13, 2018

Baretti, M., Personeni, N., Destro, A., Santoro, A., & Rimassa, L. (2018). Emergence of KRAS-mutation in liver metastases after an anti-EGFR treatment in patient with colorectal cancer: Are we aware of the therapeutic impact of intratumor heterogeneity? Cancer Biology & Therapy, 19(8), 659–663. https://doi.org/10.1080/15384047.2018.1450117

Samiul Amin

Professor of Practice at University of Miami Professor of Practice and Director ECAP at University of Miami with expertise in Formulation Design, Rheology, Biosurfactants, Biopolymers and Materials Science.
Most Relevant Research Interests
Pharmacology
Other Research Interests (50)
Complex Fluids
Rheology
Microrheology
Protein Aggregation
Colloid and Surface Chemistry
And 45 more
About
With over 22 years of industry and academic experience in SoftMatter, colloids, and complex fluids, I am a Professor of Practice and Director of the Engineering Corporate Affiliate Program (ECAP) at the University of Miami. My mission is to bridge the gap between engineering education/research and industry needs, and to foster a culture of creativity, innovation, and entrepreneurship among students and faculty. I am also co-founder of FastFormulator a Formulation Design Lab developing novel sustainable formulations for a wide range of industries utilizing an integrated approach of High THroughput FOrmulation Automation/Advanced CHaracterization/AI-ML and based on deep colloid science/complex fluids insights. <br> As a leading researcher and consultant in formulation design and performance optimization of consumer, cosmetic, biopharmaceutical, and homecare products, I collaborate with multiple global companies and organizations to develop novel and sustainable solutions based on high throughput formulation, AI/ML, advanced characterization and novel sustainable materials. I also teach courses in polymers, surfactants, emulsions, rheology, tribology, and innovation management, and chair international conferences in my field of expertise. I am passionate about advancing the science and engineering of complex fluids and cosmetics, and sharing my knowledge and insights with the next generation of engineers and innovators.
Most Relevant Publications (1+)

68 total publications

Investigating the Influence of Polysorbate 20/80 and Polaxomer P188 on the Surface & Interfacial Properties of Bovine Serum Albumin and Lysozyme

Pharmaceutical Research / May 20, 2019

Begum, F., & Amin, S. (2019). Investigating the Influence of Polysorbate 20/80 and Polaxomer P188 on the Surface &amp; Interfacial Properties of Bovine Serum Albumin and Lysozyme. Pharmaceutical Research, 36(7). https://doi.org/10.1007/s11095-019-2631-6

Professor Sinead McGilloway

Professor of Family and Community Mental Health and Founder Director of the Centre for Mental Health and Community Research (CMHCR), Maynooth University Department of Psychology (THE 2023 ranking: 126-150) and Social Sciences Institute.
Most Relevant Research Interests
Pharmacology
Other Research Interests (37)
Education
Public Health, Environmental and Occupational Health
Health Policy
Sociology and Political Science
Social Sciences (miscellaneous)
And 32 more
About
Professor Sinead McGilloway is Professor of Family and Community Mental Health and Founder Director of the *Centre for Mental Health and Community Research* in the Maynooth University Dept of Psychology and Social Sciences Institute ([www.cmhcr.eu](http://www.cmhcr.eu/)). She is a Chartered Psychologist and Chartered Scientist with the British Psychological Society (BPS) and an Associate Fellow of the BPS. She has extensive experience in undertaking engaged policy- and practice-relevant research with a focus on child and adult mental health and well-being (incl. vulnerable/ marginalised groups), early intervention/prevention and service evaluation. She has won significant research funding to date, is widely published and has won a number of awards, including the Lionel Hersov Memorial (Team) Award by the (UK) Association for Child and Adolescent Mental Health (2022), an Irish Research Council Research Ally prize (2022) and Maynooth University Faculty of Social Sciences Research Achievement Award 2021.
Most Relevant Publications (1+)

46 total publications

β2-Adrenoceptor antagonism in anxiety

European Neuropsychopharmacology / Nov 01, 1990

Cooper, S. J., Kelly, C. B., McGilloway, S., & Gilliland, A. (1990). β2-Adrenoceptor antagonism in anxiety. European Neuropsychopharmacology, 1(1), 75–77. https://doi.org/10.1016/0924-977x(90)90016-4

Sumeet K. Tiwari

Bioinformatic researcher at Quadram Institute Bioscience
Most Relevant Research Interests
Pharmacology
Other Research Interests (20)
Bioinformatics
Microbiology (medical)
Microbiology
Virology
Infectious Diseases
And 15 more
About
I'm an experienced bioinformatician with experience in analysing OMIC data (Meta-Genomics, RNASeq and Genomics).
Most Relevant Publications (1+)

16 total publications

Molecular Epidemiology and Genome Dynamics of New Delhi Metallo-β-Lactamase-Producing Extraintestinal Pathogenic Escherichia coli Strains from India

Antimicrobial Agents and Chemotherapy / Nov 01, 2016

Ranjan, A., Shaik, S., Mondal, A., Nandanwar, N., Hussain, A., Semmler, T., Kumar, N., Tiwari, S. K., Jadhav, S., Wieler, L. H., & Ahmed, N. (2016). Molecular Epidemiology and Genome Dynamics of New Delhi Metallo-β-Lactamase-Producing Extraintestinal Pathogenic Escherichia coli Strains from India. Antimicrobial Agents and Chemotherapy, 60(11), 6795–6805. https://doi.org/10.1128/aac.01345-16

Katelyn Katelyn Masiuk

Co-Founder and CSO at Immunovec
Most Relevant Research Interests
Pharmacology
Other Research Interests (13)
Cell Biology
Genetics
Molecular Medicine
Molecular Biology
Drug Discovery
And 8 more
About
Katelyn Masiuk is the co-founder and Chief Scientific Officer of ImmunoVec. She is also a medical student in the MSTP program at UCLA. Her research interests include immunology and virology.
Most Relevant Publications (2+)

13 total publications

Editing the Sickle Cell Disease Mutation in Human Hematopoietic Stem Cells: Comparison of Endonucleases and Homologous Donor Templates

Molecular Therapy / Aug 01, 2019

Romero, Z., Lomova, A., Said, S., Miggelbrink, A., Kuo, C. Y., Campo-Fernandez, B., Hoban, M. D., Masiuk, K. E., Clark, D. N., Long, J., Sanchez, J. M., Velez, M., Miyahira, E., Zhang, R., Brown, D., Wang, X., Kurmangaliyev, Y. Z., Hollis, R. P., & Kohn, D. B. (2019). Editing the Sickle Cell Disease Mutation in Human Hematopoietic Stem Cells: Comparison of Endonucleases and Homologous Donor Templates. Molecular Therapy, 27(8), 1389–1406. https://doi.org/10.1016/j.ymthe.2019.05.014

Improving Gene Therapy Efficiency through the Enrichment of Human Hematopoietic Stem Cells

Molecular Therapy / Sep 01, 2017

Masiuk, K. E., Brown, D., Laborada, J., Hollis, R. P., Urbinati, F., & Kohn, D. B. (2017). Improving Gene Therapy Efficiency through the Enrichment of Human Hematopoietic Stem Cells. Molecular Therapy, 25(9), 2163–2175. https://doi.org/10.1016/j.ymthe.2017.05.023

Example pharmacology projects

How can companies collaborate more effectively with researchers, experts, and thought leaders to make progress on pharmacology?

Optimizing Drug Formulations

A pharmaceutical company can collaborate with a Pharmacology expert to optimize the formulation of a drug, ensuring its stability, bioavailability, and therapeutic efficacy. The researcher can provide insights into the physicochemical properties of the drug, recommend suitable excipients, and suggest formulation strategies to enhance drug delivery and absorption.

Identifying New Drug Targets

By partnering with a Pharmacology researcher, a biotechnology company can identify novel drug targets for various diseases. The expert can analyze disease mechanisms, molecular pathways, and receptor interactions to identify potential therapeutic targets. This collaboration can lead to the development of innovative drugs with improved efficacy and specificity.

Improving Clinical Trial Design

A contract research organization (CRO) can collaborate with a Pharmacology expert to improve the design of clinical trials. The researcher can provide insights into appropriate dosing regimens, patient selection criteria, and outcome measures. This collaboration can enhance the efficiency and reliability of clinical trials, leading to faster drug approvals and reduced development costs.

Assessing Drug Safety and Efficacy

A pharmaceutical company can work with a Pharmacology expert to assess the safety and efficacy of their drugs. The researcher can conduct preclinical studies, evaluate drug-drug interactions, and assess potential adverse effects. This collaboration can help identify and mitigate safety risks, ensuring the development of safe and effective medications.

Navigating Regulatory Affairs

Companies can collaborate with Pharmacology experts to navigate the complex landscape of regulatory affairs. These researchers can provide guidance on regulatory requirements, assist in preparing documentation for regulatory submissions, and ensure compliance with safety and efficacy standards. This collaboration can streamline the regulatory process and expedite the approval of new drugs.